SNY

Sanofi ADS
D

SNY

Arincen75/100B

Sanofi ADS income statement 1999–2026

50.98B EUR over the last twelve months, and 46.72B EUR in fiscal year 2025.

Revenue Operating income Net income

Click a line's chart icon in the table to add it to the chart; hover over it for a quick look.

Fiscal year
TTM
30 Sept 2026
FY2025
31 Dec 2025
FY2024
31 Dec 2024
FY2023
31 Dec 2023
FY2022
31 Dec 2022
FY2021
31 Dec 2021
FY2020
31 Dec 2020
FY2019
31 Dec 2019
FY2018
31 Dec 2018
FY2017
31 Dec 2017
FY2016
31 Dec 2016
Revenue
50.98B46.72B44.29B41.62B40.56B39.18B37.37B37.63B35.68B36.22B34.70B
Revenue growth
+20.98%+5.49%+6.41%+2.61%+3.54%+4.83%-0.70%+5.48%-1.50%+4.40%-0.47%
Cost of revenue
13.42B13.05B13.21B12.63B11.88B12.26B12.16B11.98B11.44B11.61B10.70B
Gross profit
37.57B33.67B31.08B28.99B28.68B26.92B25.21B25.65B24.24B24.61B24.00B
Gross margin
73.68%72.07%70.18%69.66%70.71%68.72%67.46%68.17%67.95%67.94%69.16%
Research and development
8.12B7.84B7.39B6.51B6.50B5.69B5.53B6.02B5.89B5.47B5.17B
Selling, general and administrative
10.02B10.24B9.18B8.93B8.74B9.56B9.39B9.88B9.86B10.07B9.48B
Operating expenses
29.25B24.07B23.83B22.03B18.52B18.79B11.10B22.60B19.57B18.80B17.46B
8.32B9.60B7.25B6.96B10.16B8.13B14.11B3.05B4.68B5.80B6.53B
Operating income growth
+5.28%+32.34%+4.20%-31.51%+25.06%-42.42%+362.57%-34.75%-19.43%-11.13%+16.13%
Operating margin
16.32%20.54%16.38%16.72%25.05%20.74%37.77%8.11%13.11%16.02%18.82%
Interest income
237.69M331.00M457.53M530.50M168.96M3.13M34.43M89.71M74.37M53.97M59.03M
Interest expense
586.41M626.00M622.58M512.82M384.80M377.37M430.84M536.28M486.48M333.43M399.50M
Other non-operating income
-2.41B-3.58B-494.00M-845.00M-170.00M-289.00M24.00M-44.00M228.00M-188.00M-720.00M
Pretax income
5.91B6.02B6.76B6.12B9.99B7.84B14.14B3.01B4.90B5.62B5.81B
Income tax
1.72B1.04B1.20B1.02B1.91B1.56B1.81B121.00M481.00M1.72B1.33B
Effective tax rate
29.06%17.33%17.82%16.63%19.11%19.88%12.78%4.02%9.81%30.66%22.80%
4.18B7.81B5.56B5.40B8.37B6.22B12.29B2.75B4.31B8.42B4.71B
Net income growth
-54.16%+40.52%+2.96%-35.49%+34.52%-49.38%+346.41%-36.04%-48.84%+78.72%+9.84%
Net margin
8.19%16.72%12.55%12.98%20.64%15.89%32.90%7.32%12.07%23.24%13.57%
Basic shares
2.41B2.44B2.50B2.50B2.50B2.51B2.51B2.50B2.49B2.51B2.57B
Diluted shares
2.41B2.44B2.50B2.51B2.50B2.51B2.51B2.50B2.49B2.51B2.57B
Change in diluted shares
-2.71%-2.48%-0.40%+0.36%-0.05%-0.09%+0.30%+0.22%-0.78%-2.31%-1.50%
EPS (basic)
0.593.202.192.153.192.494.911.141.731.501.83
EPS (diluted)
0.613.202.192.153.182.494.911.141.733.361.83
EPS growth
-84.16%+46.12%+1.86%-32.39%+27.71%-49.29%+330.70%-34.10%-48.51%+83.61%+11.59%
Dividends per share
2.422.202.041.902.041.911.751.741.861.581.63
Dividend growth
+10.19%+7.78%+7.04%-6.90%+7.24%+8.73%+0.81%-6.56%+18.01%-3.25%+0.74%
EBITDA
15.56B12.48B11.03B11.39B13.51B11.54B17.53B10.66B9.18B9.64B9.90B
EBITDA margin
30.52%26.71%24.91%27.37%33.31%29.45%46.90%28.33%25.73%26.61%28.53%
EBIT
9.58B6.80B7.45B6.96B10.40B8.19B14.21B3.22B4.90B5.95B6.60B

Figures in EUR. Shares and EPS are adjusted for stock splits. Quarterly growth is on the same quarter a year before; TTM is the last four quarters.

Common questions about Sanofi ADS's income statement

Source: Financial Modeling Prep

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.